Insider Selling: Charles River Laboratories Intl. Inc (CRL) Director Sells 4,066 Shares of Stock

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) Director Deborah Turner Kochevar sold 4,066 shares of the company’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $123.66, for a total transaction of $502,801.56. Following the completion of the transaction, the director now owns 10,190 shares of the company’s stock, valued at approximately $1,260,095.40. The sale was disclosed in a filing with the SEC, which is available at this link.

CRL stock traded down $0.51 on Wednesday, hitting $124.20. The company’s stock had a trading volume of 18,742 shares, compared to its average volume of 429,049. Charles River Laboratories Intl. Inc has a 1 year low of $96.70 and a 1 year high of $130.66. The company has a market cap of $5.93 billion, a price-to-earnings ratio of 23.55, a price-to-earnings-growth ratio of 1.55 and a beta of 0.66. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The firm had revenue of $585.30 million during the quarter, compared to the consensus estimate of $570.65 million. During the same quarter in the prior year, the firm earned $1.29 EPS. Charles River Laboratories Intl.’s revenue for the quarter was up 24.8% on a year-over-year basis. analysts anticipate that Charles River Laboratories Intl. Inc will post 5.91 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC purchased a new stake in Charles River Laboratories Intl. in the 1st quarter valued at $105,000. NumerixS Investment Technologies Inc purchased a new stake in Charles River Laboratories Intl. in the 2nd quarter valued at $122,000. Adviser Investments LLC purchased a new stake in Charles River Laboratories Intl. in the 1st quarter valued at $152,000. Wsfs Capital Management LLC purchased a new stake in Charles River Laboratories Intl. in the 2nd quarter valued at $203,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in Charles River Laboratories Intl. in the 2nd quarter valued at $212,000. Hedge funds and other institutional investors own 97.76% of the company’s stock.

Several research analysts have recently issued reports on CRL shares. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 target price for the company in a report on Friday, May 11th. TheStreet upgraded shares of Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a report on Thursday, May 10th. KeyCorp upgraded shares of Charles River Laboratories Intl. from a “sector weight” rating to an “overweight” rating and upped their target price for the company from $115.85 to $130.00 in a report on Friday, June 15th. Bank of America upped their target price on shares of Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a report on Monday, July 16th. Finally, Royal Bank of Canada upgraded shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 target price for the company in a report on Tuesday, July 17th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $125.40.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Should you buy a closed-end mutual fund?

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply